1.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
|
|
2.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-03112, 050909, U01CA132194, CINJ-050801, 050801, 0220080281, NCT00813423
|
|
3.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110111, 11-C-0111, NCT01313429
|
|
4.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110148, 11-C-0148, NCT01341496
|
|
5.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02500, UPCI 10-115, CDR0000700997, U01CA069856, U01CA099168, U01CA062502, U01CA070095, U01CA062505, 8808, NCT01366144
|
|
6.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115717, NCT01458067
|
|
7.
|
Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 19809, NCT01132014
|